Tom writes: The bottom line is that I shall be selling the FIML shares but am giving you at least 24 hours notice. This is NOT a financial call but an ethical call, as I explain, and Steve Moore, who will cover Yourgene going forward, explains why he is not selling his shares on the results and where he sees them going...
As you know my only concern over Yourgene (YGEN), where I remain a loyal shareholder, is an ethical one. A full year trading update, though badly crafted - note to board: sack useless PR - is incredibly impressive and removes any financial doubts. The shares have not yet responded. They will. At a 12.75p offer fill your boots at up to 15p – this stock will soon be in the roaring twenties and is a STRONG BUY...
In its dark days as Premaitha (NIPT), this company was dogged by bully boy US giant Illumina which tried to put it out of business with a claim for patent infringement. New boss Lynn Rees not only sorted that out but as part of the deal, entered a partnership with Illumina. Now the bully boys are on our side.
There is, for we long suffering shareholders, light at the end of the tunnel though a first read of results from Yourgene (YGEN) for the six months to 30 September 2018 does not exactly bring a warm feeling. But there is a new CEO, Lyn Rees, and he seems to have a clue. Of course the Illumina patent issue was only settled during this period and that should be born in mind. To the numbers…
Tom Winnifrith writes and has also discussed this in bearcast HERE: We ordinary shareholders in Premaitha (NIPT) have suffered for many years and shown enormous loyalty. News released well after the market close of a £2.5 million placing at 10p might thus seem like a kick in the teeth by a management treating us with contempt. I am afraid the story is far worse.
We are getting increasingly used to Premaitha (NIPT) announcing more and more large non-UK distribution agreements. And fear not there will be much more on that front in the weeks and months that lie ahead. It will be a hot summer for Premaitha and for we loyal shareholders. But, for now, there is something a bit different.
Updating on Premaitha Health (NIPT) earlier in the week we noted an up to £2.1 million loan facility agreement to fund costs related to the ongoing Illumina litigation and that a Form of Order hearing is scheduled to take place early this week. The shares are currently rising towards 5p on the back of a UK High Court grants right to appeal announcement from the company…
After the Illumina legal setback for Premaitha (NIPT) we suggested that the cost of that setback was very manageable – a maximum of less than £2 million is what we hear – and that the underlying business is doing very well. That view is reaffirmed by latest news.
This is not the news we Premaitha (NIPT) shareholders wanted and it is clearly bad news. The question is how bad? The UK High Court has upheld three patent claims made by Illumina against Premaitha.
Premaitha (NIPT) has announced that it has been approved for Brazilian Good Manufacturing Practice for the company's IONA test by Brazil's regulatory authority, the Agência Nacional de Vigilância Sanitária. Jolly good news and it strengthens the story, but it is not the elephant in the room is it?
Premaitha Health (NIPT) has announced that it has entered into a further extension of the investment agreement with Thermo Fisher Scientific announced on 14 December 2015 and extended as announced on 23 September 2016. This is good news.
Premaitha (NIPT) has updated investors on its progress in India where it claims now to have representation in 9 of the 15 most populous states with several of the largest nationwide pathology laboratory groups running Yourgene's NIPT workflow in-house.
Premaitha (NIPT) has updated on trading in the year to March 31 2017. Of course, what matters is not historic trading but the future, that is to say the patent challenge by US corporate fascist bully-boys Ilumina. However, some numbers do matter...
The issue with Genoma was flagged up in the interims pre-Christmas. It owes Premaitha (NIPT) £750,000. That debt looks like a bad debt because the Swiss company has - despite its parent company concluding a fundraise - been having financial issues. So Premaitha has gone to court and had Genoma made bankrupt.
Premaitha (NIPT) announced late last week its results for the year to March 31 2016. Given the pace of events here these historic numbers do not mean that much but for the record:
Apologies for the delay in commenting on this RNS which landed on Friday. We wanted to speak to Adam Reynolds and we have now done so. This is just the start of the good news and ahead of results tomorrow Premaitha (NIPT) shares are a buy.
Although the twit who handles PR for Premaitha (NIPT) has again contrived to confuse the issue with some garbled press releases this morning there is actually some good news. Fire the idiot PR man and investors could get excited as they discover what is really going on.
The shares of Premaitha (NIPT) have been all over the shop since what was a cracking year end trading statement on Monday. The reason is the cackhanded disposal of Rupert Lywood's remaining 17.9% stake. We thought he was locked in following his last dump on 9 March and a statement signed off by broker Finncap. Weasel words. His shares were placed by Finncap at just 6.5p with directors taking some and solid institutions Helium, Henderson and Hargreave Hale taking the rest. The overhang is now gone but boy has it crushed the shares. Without Lywood's "assistance" since last summer we think the shares would be 20p today. But he is now out of the picture.
Premaitha Health (NIPT) has announced further international expansion of its customer base and updated on UK litigation timing
Premaitha Health (NIPT) has noted an announcement from Illumina, Inc. of patent infringement suits against Premaitha's customer in Poland and Ariosa Diagnostics, a subsidiary of Roche, and their customer, The Doctors Laboratory, in the UK, while reiterating that it “continues to make a robust defence against earlier claims by Illumina and the board is confident that the IONA test does not infringe the patents as claimed in the earlier cases or in relation to today's announcement”
Ok this was one of my less successful share tips of the year for 2015 but this time it really will come good. That will be the prompt for guffaws of laughter from Wildes, who is currently sitting on a sinking lifeboat from the doomed SS LGO Energy. But he who laughs last...
Premaitha Health (NIPT) has announced an agreement with the leading distributor of scientific products in Greece (Antisel SA) to provide its IONA test to clinical laboratories in the region and that it has been informed that American company Illumina, Inc. has added a third patent to its suit against it. Buy, sell or hold?